TISIDB

Summary
Symbol	MAEA
Name	macrophage erythroblast attacher
Aliases	EMP; GID9; GID complex subunit 9, FYV10 homolog (S. cerevisiae); EMLP; HLC-10; GID complex subunit 9, FYV10 ......
Chromosomal Location	4p16.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway

> Subcellular Location, Domain and Function [ TOP ]
Subcellular Location	Nucleus matrix Cell membrane Cytoplasm, cytoskeleton Note=Localized as nuclear speckled-like pattern.
Domain	PF10607 CTLH/CRA C-terminal to LisH motif domain
Function	Plays a role in erythroblast enucleation and in the development of the mature macrophages. Mediates the attachment of erythroid cell to mature macrophages, in correlation with the presence of MAEA at cell surface of mature macrophages; This MAEA-mediated contact inhibits erythroid cells apoptosis. Participates in erythroblastic island formation, which is the functional unit of definitive erythropoiesis. Associates with F-actin to regulate actin distribution in erythroblasts and macrophages. May contribute to nuclear architecture and cells division events.

> Gene Ontology [ TOP ]
Biological Process	GO:0002262 myeloid cell homeostasis GO:0007346 regulation of mitotic cell cycle GO:0010498 proteasomal protein catabolic process GO:0021700 developmental maturation GO:0030099 myeloid cell differentiation GO:0030218 erythrocyte differentiation GO:0033028 myeloid cell apoptotic process GO:0033032 regulation of myeloid cell apoptotic process GO:0033033 negative regulation of myeloid cell apoptotic process GO:0034101 erythrocyte homeostasis GO:0042787 protein ubiquitination involved in ubiquitin-dependent protein catabolic process GO:0043161 proteasome-mediated ubiquitin-dependent protein catabolic process GO:0043249 erythrocyte maturation GO:0043353 enucleate erythrocyte differentiation GO:0048469 cell maturation GO:0048821 erythrocyte development GO:0048822 enucleate erythrocyte development GO:0048872 homeostasis of number of cells GO:0061515 myeloid cell development
Molecular Function	GO:0003779 actin binding GO:0004842 ubiquitin-protein transferase activity GO:0019787 ubiquitin-like protein transferase activity
Cellular Component	GO:0005819 spindle GO:0005826 actomyosin contractile ring GO:0005938 cell cortex GO:0015629 actin cytoskeleton GO:0016363 nuclear matrix GO:0030863 cortical cytoskeleton GO:0030864 cortical actin cytoskeleton GO:0032153 cell division site GO:0032155 cell division site part GO:0034399 nuclear periphery GO:0034657 GID complex GO:0044448 cell cortex part GO:0070938 contractile ring GO:0099568 cytoplasmic region

> KEGG and Reactome Pathway [ TOP ]
KEGG	-
Reactome	-

Summary
Symbol	MAEA
Name	macrophage erythroblast attacher
Aliases	EMP; GID9; GID complex subunit 9, FYV10 homolog (S. cerevisiae); EMLP; HLC-10; GID complex subunit 9, FYV10 ......
Chromosomal Location	4p16.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Literatures that report relations between MAEA and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.

> Text Mining [ TOP ]
There is no record.

Summary
Symbol	MAEA
Name	macrophage erythroblast attacher
Aliases	EMP; GID9; GID complex subunit 9, FYV10 homolog (S. cerevisiae); EMLP; HLC-10; GID complex subunit 9, FYV10 ......
Chromosomal Location	4p16.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.

> High-throughput Screening

[ TOP ]

Statistical results of MAEA in screening data sets for detecting immune reponses.

PMID	Screening System	Cancer Type	Cell Line	Data Set	Statistical Results	Relation to immunity
29301958	CRISPR-Cas9	melanoma	B16F10	Pmel-1 T cell	logFC: -3.00; FDR: 0.02000	Resistant to T cell-mediated killing
29301958	CRISPR-Cas9	melanoma	B16F10	OT-1 T cell	NA/NS	NA/NS
28783722	CRISPR-Cas9	melanoma	Mel624	2CT-CRISPR	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX+Anti-PD1	STARS Score: 4.88; FDR: 0.003	Resistant to T cell-mediated killing
28723893	CRISPR-Cas9	melanoma	B16	GVAX	STARS Score: 3.55; FDR: 0.047	Resistant to T cell-mediated killing
25691366	RNAi	Breast cancer	MCF7	Luc-CTL assay	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Primary screen	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Secondary screen	NA/NS	NA/NS

Summary
Symbol	MAEA
Name	macrophage erythroblast attacher
Aliases	EMP; GID9; GID complex subunit 9, FYV10 homolog (S. cerevisiae); EMLP; HLC-10; GID complex subunit 9, FYV10 ......
Chromosomal Location	4p16.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders

> Expression difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the expression difference of MAEA in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	Log2 (Fold Change)	P value
1	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	14	12	0.219	0.352
2	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	6	5	0.205	0.93
3	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	7	0.223	0.902
4	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0.172	0.574
5	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0.374	0.861
6	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	-0.084	0.975
7	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	26	23	-0.073	0.831
8	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	15	11	0.074	0.961
9	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	11	12	-0.254	0.882
10	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	4	8	0.436	0.79
11	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	2	0	0	1
12	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	2	8	0.774	0.748
13	29443960	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	68	230	0.103	0.141

> Mutation difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the mutation difference of MAEA in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	% Mut/Res	% Mut/NRes	% Diff (R vs NR)	Pval
1	25765070	Non-small cell lung cancer (NSCLC)	all	Anti-PD-1 (pembrolizumab)	14	17	0	0	0	1
2	25765070	Non-small cell lung cancer (NSCLC)	smoking	Anti-PD-1 (pembrolizumab)	10	3	0	0	0	1
3	25765070	Non-small cell lung cancer (NSCLC)	non-smoking	Anti-PD-1 (pembrolizumab)	4	14	0	0	0	1
4	26359337	Melanoma	all	Anti-CTLA-4 (ipilimumab)	27	73	3.7	2.7	1	1
5	26359337	Melanoma	BRAFi	Anti-CTLA-4 (ipilimumab)	0	14	0	0	0	1
6	26359337	Melanoma	non-BRAFi	Anti-CTLA-4 (ipilimumab)	27	59	3.7	3.4	0.3	1
7	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	21	17	0	0	0	1
8	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	6	0	0	0	1
9	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	13	11	0	0	0	1
10	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	22.2	0	22.2	0.12
11	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0	0	0	1
12	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	50	0	50	0.109
13	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	38	27	2.6	0	2.6	1
14	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	22	13	0	0	0	1
15	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	16	14	6.2	0	6.2	1
16	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	11	13	0	0	0	1
17	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	6	1	0	0	0	1
18	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	5	12	0	0	0	1

Summary
Symbol	MAEA
Name	macrophage erythroblast attacher
Aliases	EMP; GID9; GID complex subunit 9, FYV10 homolog (S. cerevisiae); EMLP; HLC-10; GID complex subunit 9, FYV10 ......
Chromosomal Location	4p16.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of MAEA. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.

> Lymphocyte [ TOP ]

Summary
Symbol	MAEA
Name	macrophage erythroblast attacher
Aliases	EMP; GID9; GID complex subunit 9, FYV10 homolog (S. cerevisiae); EMLP; HLC-10; GID complex subunit 9, FYV10 ......
Chromosomal Location	4p16.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of MAEA. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by MAEA. > Immunoinhibitor > Immunostimulator > MHC molecule

> Immunoinhibitor [ TOP ]

> Immunostimulator [ TOP ]

> MHC molecule [ TOP ]

Summary
Symbol	MAEA
Name	macrophage erythroblast attacher
Aliases	EMP; GID9; GID complex subunit 9, FYV10 homolog (S. cerevisiae); EMLP; HLC-10; GID complex subunit 9, FYV10 ......
Chromosomal Location	4p16.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of MAEA. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor

> Chemokine [ TOP ]

> Receptor [ TOP ]

Summary
Symbol	MAEA
Name	macrophage erythroblast attacher
Aliases	EMP; GID9; GID complex subunit 9, FYV10 homolog (S. cerevisiae); EMLP; HLC-10; GID complex subunit 9, FYV10 ......
Chromosomal Location	4p16.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Distribution of MAEA expression across immune and molecular subtypes. > Immune subtype > Molecular subtype

> Immune subtype [ TOP ]

> Molecular subtype [ TOP ]

Summary
Symbol	MAEA
Name	macrophage erythroblast attacher
Aliases	EMP; GID9; GID complex subunit 9, FYV10 homolog (S. cerevisiae); EMLP; HLC-10; GID complex subunit 9, FYV10 ......
Chromosomal Location	4p16.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Associations between MAEA and clinical features. > Overall survival analysis > Cancer stage > Tumor grade

> Overall survival [ TOP ]

> Stage [ TOP ]

> Grade [ TOP ]

Summary
Symbol	MAEA
Name	macrophage erythroblast attacher
Aliases	EMP; GID9; GID complex subunit 9, FYV10 homolog (S. cerevisiae); EMLP; HLC-10; GID complex subunit 9, FYV10 ......
Chromosomal Location	4p16.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Drugs targeting MAEA collected from DrugBank database.

> Drugs from DrugBank database

[ TOP ]

Details on drugs targeting MAEA.

ID	Name	Drug Type	Targets	#Targets
DB05389	WF10	Small Molecule	CD163, MAEA	2

Browse MAEA